🇺🇸 Eptifibatide (Integrilin) in United States
10 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 10
Most-reported reactions
- Post Procedural Complication — 2 reports (20%)
- Post Procedural Pain — 2 reports (20%)
- Blood Creatine Phosphokinase Mb Increased — 1 report (10%)
- Bloody Discharge — 1 report (10%)
- Ecchymosis — 1 report (10%)
- Enzyme Abnormality — 1 report (10%)
- Groin Pain — 1 report (10%)
- Post Procedural Haematoma — 1 report (10%)
Other Cardiovascular approved in United States
Frequently asked questions
Is Eptifibatide (Integrilin) approved in United States?
Eptifibatide (Integrilin) does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Eptifibatide (Integrilin) in United States?
Organon and Co is the originator. The local marketing authorisation holder may differ — check the official source linked above.